RecruitingPhase 4NCT03718403
Effect of Theophylline in Pseudohypoparathyroidism
Sponsor
Massachusetts General Hospital
Enrollment
100 participants
Start Date
Nov 11, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism.
Eligibility
Min Age: 5 YearsMax Age: 21 Years
Inclusion Criteria2
- Subjects with known diagnosis of PHP1A and PHP1B
- Age >5 years
Exclusion Criteria13
- Significant kidney disease, i.e. any CKD stage
- Hypercalciuria
- Kidney stones
- Severe Heart disease
- Uncontrolled seizure disorder
- Peptic ulcer
- Liver dysfunction
- Bleeding disorder
- Allergy to theophylline preparation
- Muscle disorder
- Infection
- Any neurologic disease
- Chronic drugs interacting with theophylline
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTheophylline
Theophylline will be given to maintain a peak level between 10-15 mcg/mL
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03718403